Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06403436 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
A Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by TOLREMO therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT06403436: Recruiting Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by TOLREMO therapeutics.
NCT06403436 is a Phase 1 study of Cancer and Advanced Solid Tumor that is actively recruiting participants, run by TOLREMO therapeutics. The registered enrollment target is 50 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06403436, a Phase 1 study of Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by TOLREMO therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG TT125-802
Study Locations (7)
Other
- NEXT Oncology Barcelona - Barcelona
- Vall d'Hebron Institute of Oncology - Barcelona
- NEXT Oncology Madrid - Madrid
- Ente Ospedaliero Cantonale - Bellinzona
- Centre Hospitalier Universitaire Vaudois - Lausanne
Tennessee
- Sarah Cannon Research Institute Oncology Partners - Nashville
Virginia
- NEXT Oncology Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06403436 shows while recruiting
NCT06403436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 8 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which TT125-802 is the first listed.
NCT06403436 lists 7 locations in 3 states (Other, Tennessee, Virginia).
Frequently Asked Questions
What is clinical trial NCT06403436 about?
NCT06403436 is a clinical study titled "A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors". The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.
What is the current status of trial NCT06403436?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-11-07. Estimated completion is 2026-12.
What conditions does trial NCT06403436 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, NSCLC, Kras G12C, Squamous Cell Lung Cancer.
What interventions are being tested in trial NCT06403436?
The interventions under investigation include: TT125-802 (DRUG).
Who is sponsoring clinical trial NCT06403436?
This trial is sponsored by TOLREMO therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06403436 being conducted?
This trial has 7 study locations across Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06403436's enrollment target sits among peer trials
50 422nd of 615 higher than 179 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI